Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
n this study, approximately 30 patients with relapsed or refractory non-Hodgkin's lymphoma
(NHL) were recruited for a single reinfusion of IM19-CD28 and IM19-41BB CAR-T cells. Assess
the safety, tolerability of treatment, and initially observe the efficacy.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Immunochina Medical Science & Technology Co., Ltd.